Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Practical Approach for Angina and Non-Obstructive Coronary Arteries: A State-of-the-Art Review

  • Coen K.M. Boerhout (Heart Center, Amsterdam UMC) ;
  • Marcel A.M. Beijk (Heart Center, Amsterdam UMC) ;
  • Peter Damman (Department of Cardiology, Radboud University Medica Centre) ;
  • Jan J. Piek (Heart Center, Amsterdam UMC) ;
  • Tim P. van de Hoef (Division Heart and Lung, Department of Cardiology, University Medical Centre Utrecht)
  • Received : 2023.05.12
  • Accepted : 2023.05.19
  • Published : 2023.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

Anginal symptoms are frequently encountered in patients without the presence of significant obstructive coronary artery disease (CAD). It is increasingly recognized that vasomotor disorders, such as an abnormal vasodilatory capacity of the coronary microcirculation or coronary vasospasm, are the dominant pathophysiological substrate in these patients. Although the evidence with respect to angina in patients with non-obstructive coronary arteries is accumulating, the diagnosis and treatment of these patients remains challenging. In this review, we aimed to provide a comprehensive overview regarding the pathophysiological origins of angina with non-obstructive coronary arteries disorders and its diagnostic and therapeutic considerations. Hereby, we provide a practical approach for the management of patents with angina and non-obstructive CAD.

Keywords

References

  1. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med 2010;362:886-95.
  2. Jespersen L, Hvelplund A, Abildstrom SZ, et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J 2012;33:734-44.
  3. Feenstra RG, Boerhout CK, Woudstra J, et al. Presence of coronary endothelial dysfunction, coronary vasospasm, and adenosine-mediated vasodilatory disorders in patients with ischemia and nonobstructive coronary arteries. Circ Cardiovasc Interv 2022;15:e012017.
  4. Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol 2018;72:2841-55.
  5. Kunadian V, Chieffo A, Camici PG, et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international. EuroIntervention 2021;16:1049-69.
  6. Crea F, Camici PG, De Caterina R, Lanza GA. 17. Chronic ischaemic heart disease. In: Camm AJ, Luscher TF, Serruys PW, editors. The ESC Textbook of Cardiovascular Medicine. 2nd ed. Oxford: Oxford University Press; 2006. 
  7. Mosher P, Ross J Jr, McFate PA, Shaw RF. Control of coronary blood flow by an autoregulatory mechanism. Circ Res 1964;14:250-9.
  8. Deussen A, Ohanyan V, Jannasch A, Yin L, Chilian W. Mechanisms of metabolic coronary flow regulation. J Mol Cell Cardiol 2012;52:794-801.
  9. Chilian WM. Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation 1997;95:522-8.
  10. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res 1990;66:1561-75.
  11. Layland J, Carrick D, Lee M, Oldroyd K, Berry C. Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc Interv 2014;7:581-91.
  12. Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J 2014;35:1101-11.
  13. Rahman H, Demir OM, Khan F, et al. Physiological stratification of patients with angina due to coronary microvascular dysfunction. J Am Coll Cardiol 2020;75:2538-49.
  14. Rahman H, Ryan M, Lumley M, et al. Coronary microvascular dysfunction is associated with myocardial ischemia and abnormal coronary perfusion during exercise. Circulation 2019;140:1805-16.
  15. Boerhout CKM, de Waard GA, Lee JM, et al. Prognostic value of structural and functional coronary microvascular dysfunction in patients with non-obstructive coronary artery disease; from the multicentre international ILIAS registry. EuroIntervention 2022;18:719-28.
  16. van de Hoef TP, Bax M, Damman P, et al. Impaired coronary autoregulation is associated with long-term fatal events in patients with stable coronary artery disease. Circ Cardiovasc Interv 2013;6:329-35.
  17. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991;84:1984-92.
  18. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
  19. Beltrame JF, Crea F, Kaski JC, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J 2017;38:2565-8.
  20. Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation 2011;124:1774-82.
  21. Hubert A, Seitz A, Pereyra VM, et al. Coronary artery spasm: the interplay between endothelial dysfunction and vascular smooth muscle cell hyperreactivity. Eur Cardiol 2020;15:e12.
  22. Kuga T, Shimokawa H, Hirakawa Y, et al. Increased expression of L-type calcium channels in vascular smooth muscle cells at spastic site in a porcine model of coronary artery spasm. J Cardiovasc Pharmacol 2000;35:822-8.
  23. Kandabashi T, Shimokawa H, Miyata K, et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β. Circulation 2000;101:1319-23.
  24. Konst RE, Meeder JG, Wittekoek ME, et al. Ischaemia with no obstructive coronary arteries. Neth Heart J 2020;28:66-72.
  25. Yasue H, Nakagawa H, Itoh T, Harada E, Mizuno Y. Coronary artery spasm--clinical features, diagnosis, pathogenesis, and treatment. J Cardiol 2008;51:2-17. 
  26. Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 2010;55:2825-32.
  27. Feenstra R, Seitz A, Boerhout C, et al. Principles and pitfalls in coronary vasomotor function testing. EuroIntervention 2022;17:1271-80.
  28. Hackett D, Larkin S, Chierchia S, Davies G, Kaski JC, Maseri A. Induction of coronary artery spasm by a direct local action of ergonovine. Circulation 1987;75:577-82.
  29. Sueda S, Kohno H, Ochi T, Uraoka T, Tsunemitsu K. Overview of the pharmacological spasm provocation test: comparisons between acetylcholine and ergonovine. J Cardiol 2017;69:57-65.
  30. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013). Circ J 2014;78:2779-801.
  31. Seitz A, Feenstra R, Konst RE, et al. Acetylcholine rechallenge: a first step toward tailored treatment in patients with coronary artery spasm. JACC Cardiovasc Interv 2022;15:65-75.
  32. Gallinoro E, Candreva A, Colaiori I, et al. Thermodilution-derived volumetric resting coronary blood flow measurement in humans. EuroIntervention 2021;17:e672-9.
  33. Camici PG, d'Amati G, Rimoldi O. Coronary microvascular dysfunction: mechanisms and functional assessment. Nat Rev Cardiol 2015;12:48-62.
  34. Demir OM, Boerhout CK, de Waard GA, et al. Comparison of Doppler flow velocity and thermodilution derived indexes of coronary physiology. JACC Cardiovasc Interv 2022;15:1060-70.
  35. Knuuti J, Wijns W, Saraste A, et al.. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-77.
  36. Boerhout CK, Feenstra RG, Somsen GA, et al. Coronary computed tomographic angiography as gatekeeper for new-onset stable angina. Neth Heart J 2021;29:551-6.
  37. Cha MJ, Kim WD, Won H, et al. Nationwide trends of gatekeeper to invasive coronary angiography in suspected coronary artery disease. Korean Circ J 2022;52:814-25.
  38. Dai N, Hwang D, Lee JM, et al. Association of quantitative flow ratio with lesion severity and its ability to discriminate myocardial ischemia. Korean Circ J 2021;51:126-39.
  39. Jansen TP, Konst RE, de Vos A, et al. Efficacy of diltiazem to improve coronary vasomotor dysfunction in ANOCA: the EDIT-CMD randomized clinical trial. JACC Cardiovasc Imaging 2022;15:1473-84.
  40. de Waure C, Lauret GJ, Ricciardi W, et al. Lifestyle interventions in patients with coronary heart disease: a systematic review. Am J Prev Med 2013;45:207-16.
  41. Shahin Y, Khan JA, Samuel N, Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 2011;216:7-16.
  42. Keller KB, Lemberg L. Prinzmetal's angina. Am J Crit Care 2004;13:350-4.
  43. Nishigaki K, Inoue Y, Yamanouchi Y, et al. Prognostic effects of calcium channel blockers in patients with vasospastic angina--a meta-analysis. Circ J 2010;74:1943-50.
  44. Cattaneo M, Porretta AP, Gallino A. Ranolazine: Drug overview and possible role in primary microvascular angina management. Int J Cardiol 2015;181:376-81.
  45. Leonardo F, Fragasso G, Rossetti E, et al. Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance. Cardiologia 1999;44:1065-9. 
  46. Jia Q, Shi S, Yuan G, et al. The effect of nicorandil in patients with cardiac syndrome X: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2020;99:e22167.
  47. Crooijmans C, Jansen TP, Konst RE, et al.; for NL-CFT. Design and rationale of the NetherLands registry of invasive Coronary vasomotor Function Testing (NL-CFT). Int J Cardiol 2023;379:1-8.